Crestor Patent Battle Could Have Ripple Effect: Is A Salt Equivalent To Base Compound?

Watson filed a 505(b)(2) NDA for a zinc salt of AstraZeneca’s Crestor, which AstraZeneca claims infringes its patent; if Watson prevails more generic manufacturers may pursue this pathway around a patent.